Getagraph.com logo
S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Sanntidsoppdatering for Aclaris Therapeutics Inc [ACRS]

Børs: NASDAQ Sektor: Healthcare Industri: Diagnostics & Research
Upcoming Earnings Alert

2 days till quarter result
(tns 2024-05-06)

Expected move: +/- 9.48%

BUY
75.00%
return 5.40%
SELL
40.00%
return 3.32%
Sist oppdatert3 mai 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

3.82% $ 1.360

KJøP 115613 min ago

@ $1.220

Utstedt: 14 feb 2024 @ 16:55

Avkastning: 11.48%

Forrige signal: feb 14 - 15:47

Forrige signal: Selg

Avkastning: 0.00 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Profile picture for Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
Dagens volum 683 415
Gjennomsnittsvolum 1.09M
Markedsverdi 96.92M
EPS $-0.0200 ( 2024-02-29 )
Neste inntjeningsdato ( $-0.340 ) 2024-05-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.070
ATR14 $0.00600 (0.44%)
Insider Trading
Date Person Action Amount type
2024-05-01 Walker Neal Buy 9 467 Common Stock
2024-05-01 Walker Neal Sell 2 784 Common Stock
2024-05-01 Walker Neal Sell 9 467 Restricted Stock Units
2024-04-01 Walker Neal Buy 9 467 Common Stock
2024-04-01 Walker Neal Sell 3 224 Common Stock
INSIDER POWER
76.35
Last 99 transactions
Buy: 2 282 071 | Sell: 323 641

Volum Korrelasjon

Lang: -0.07 (neutral)
Kort: -0.26 (neutral)
Signal:(45.422) Neutral

Aclaris Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
POET0.958
AACG0.946
GETVV0.946
AVIR0.946
NAKD0.945
HLIO0.944
IMPL0.944
CRTO0.944
HTCR0.941
CMMB0.94
10 Mest negative korrelasjoner
IDCC-0.95
MPRA-0.949
TZPSU-0.947
CEG-0.945
SLMBP-0.945
STRA-0.944
GALT-0.944
CALB-0.943
PRAA-0.942
MEOH-0.941

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aclaris Therapeutics Inc Korrelasjon - Valuta/Råvare

The country flag -0.31
( neutral )
The country flag -0.25
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.10
( neutral )

Aclaris Therapeutics Inc Økonomi

Annual 2023
Omsetning: $31.25M
Bruttogevinst: $13.17M (42.14 %)
EPS: $-1.270
FY 2023
Omsetning: $31.25M
Bruttogevinst: $13.17M (42.14 %)
EPS: $-1.270
FY 2022
Omsetning: $29.75M
Bruttogevinst: $17.79M (59.80 %)
EPS: $-1.360
FY 2021
Omsetning: $6.76M
Bruttogevinst: $2.05M (30.29 %)
EPS: $-2.14

Financial Reports:

No articles found.

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.